Analysis Gerresheimer’s Countdown to June: Audited Accounts Are the Only Cure
For investors tracking Gerresheimer, the past twelve months have been a brutal lesson in how quickly a mid-cap darling can unravel. The pharmaceutical packaging specialist has shed nearly 58% of...